decad
pass
sinc
appear
west
nile
viru
wnv
human
western
hemispher
new
york
citi
interv
wnv
spread
inexor
throughout
north
south
america
caus
million
infect
rang
subclin
ill
selflimit
febril
syndrom
lethal
neuroinvas
diseas
entri
unit
state
trigger
intens
research
basic
biolog
wnv
element
compris
protect
host
immun
respons
although
therapi
current
approv
use
human
sever
strategi
pursu
develop
effect
prophylaxi
treatment
review
describ
current
state
knowledg
epidemiolog
clinic
present
pathogenesi
immunobiolog
wnv
infect
highlight
progress
toward
effect
therapi
two
human
gene
identifi
suscept
loci
wnv
infect
mice
genet
defici
chemokin
receptor
associ
depress
leukocyt
traffick
increas
viral
burden
enhanc
mortal
glass
et
al
analog
genet
defici
eg
delet
gene
associ
wnvinduc
diseas
human
glass
et
al
although
individu
homozyg
allel
repres
gener
unit
state
popul
individu
laboratoryconfirm
symptomat
wnv
infect
homozyg
mutant
allel
thu
function
essenti
host
factor
resist
neuroinvas
wnv
infect
may
implic
use
antagonist
eg
maraviroc
hiv
therapi
certain
mous
strain
suscept
flavivirus
includ
wnv
map
truncat
isoform
oligoadenyl
sythetas
gene
member
ifnregul
gene
famili
involv
degrad
viral
rna
recent
studi
suggest
hypomorph
allel
human
ortholog
associ
symptomat
asymptomat
wnv
infect
lim
et
al
thu
human
variat
genet
risk
factor
initi
wnv
infect
although
diseas
sever
although
human
wnv
infect
occur
bite
infect
culex
mosquito
rout
includ
transfus
organ
transplant
placent
cross
breast
milk
result
transmiss
case
wnv
infect
identifi
transfus
blood
product
pealer
et
al
case
led
develop
implement
nucleic
acid
amplif
test
use
test
pool
individu
blood
product
sampl
busch
et
al
kleinman
et
al
petersen
epstein
tobler
et
al
larg
prevent
transmiss
transfus
busch
et
al
nucleic
acid
screen
blood
donor
complet
elimin
transfusiontransmit
wnv
infect
breakthrough
infect
occur
attribut
unit
level
viremia
sensit
screen
assay
busch
et
al
addit
transfus
associ
wnv
infect
sever
case
organ
transplant
report
desalvo
et
al
kleinschmidtdemast
et
al
kumar
et
al
kumar
et
al
fda
approv
screen
test
wnv
donat
organ
lang
rel
low
incid
wnv
infect
organ
transplant
risk
falseposit
occur
wide
scale
test
screen
mandat
kiberd
forward
although
clinic
criteria
assess
patient
suspect
wnv
infect
defin
granwehr
et
al
sejvar
et
al
diagnosi
depend
detect
antibodi
viral
nucleic
blood
cerebrospin
fluid
zhang
et
al
subset
clinic
laboratori
facil
isol
viru
directli
infect
clinic
sampl
viremia
rel
transient
often
preced
sever
neurolog
manifest
wnv
infect
nucleic
acid
test
although
quit
specif
rel
low
sensit
detect
wnv
igm
serum
csf
still
util
method
diagnost
confirm
kapoor
et
al
martin
et
al
test
sensit
carri
day
ill
nonetheless
test
within
first
hour
clinic
present
may
yield
fals
neg
result
inher
kinet
antiwnv
igm
respons
diamond
et
al
elisa
test
also
detect
antibodi
relat
flavivirus
eg
st
loui
japanes
enceph
viru
fals
posit
possibl
thu
import
obtain
histori
recent
vaccin
eg
yellow
fever
viru
foreign
travel
definit
serolog
diagnosi
wnv
infect
requir
comparison
antigen
neutral
activ
among
relat
flaviviru
famili
member
investig
diagnost
assay
util
purifi
wnv
structur
nonstructur
protein
wong
et
al
wong
et
al
may
allow
distinct
natur
infect
vaccin
immun
one
cautionari
note
wnv
igm
persist
serum
day
onset
infect
princ
et
al
roehrig
et
al
could
confound
interpret
serolog
result
patient
present
subsequ
clinic
syndrom
resembl
wnv
infect
genu
flaviviru
compos
greater
member
associ
human
diseas
dengu
yellow
fever
japanes
enceph
tickborn
enceph
west
nile
enceph
virus
import
global
caus
extens
morbid
mortal
burk
monath
flavivirus
envelop
rna
virus
singlestrand
positivepolar
genom
translat
cytoplasm
polyprotein
cleav
structur
nonstructur
protein
virusand
hostencod
proteas
brinton
lindenbach
rice
structur
protein
includ
capsid
protein
c
envelop
protein
e
function
receptor
bind
membran
fusion
viral
assembl
transmembran
protein
prm
assist
proper
fold
function
e
protein
role
nonstructur
ns
protein
fulli
delin
protein
form
viral
proteas
ntpase
rna
helicas
rnadepend
rna
polymeras
methyltransferas
antagon
host
immun
respons
wnv
infect
occur
follow
cellular
attach
receptormedi
endocytosi
although
dcsignr
v
integrin
suggest
wnv
attach
ligand
chu
ng
davi
et
al
cellular
receptor
wnv
physiolog
relev
cell
type
neuron
macrophag
remain
uncharacter
inde
recent
studi
report
wnv
entri
occur
independ
v
integrin
medigeshi
et
al
cellular
entri
wnv
requir
format
clathrinco
pit
chu
ng
krishnan
et
al
cholesterol
rich
lipid
raft
medigeshi
et
al
follow
phdepend
conform
chang
e
protein
modi
et
al
zhang
et
al
viral
endosom
membran
fuse
releas
viral
nucleocapsid
cytoplasm
allison
et
al
gollin
porterfield
upon
nucleocapsid
releas
viral
rna
associ
endoplasm
reticulum
er
membran
translat
translat
prerequisit
gener
negativestrand
rna
intermedi
serv
templat
nascent
positivestrand
genom
rna
synthesi
mackenzi
westaway
wnv
rna
synthesi
semiconserv
asymmetr
positivestrand
rna
genom
product
ten
time
effici
negativestrand
synthesi
brinton
posit
strand
rna
either
packag
within
progeni
virion
use
translat
addit
viral
protein
wnv
assembl
bud
er
form
envelop
immatur
particl
contain
prm
protein
egress
immatur
virion
undergo
matur
step
furinlik
proteas
cleav
prm
elshub
et
al
guirakhoo
et
al
stadler
et
al
result
reorgan
e
protein
distinct
homodimer
array
mukhopadhyay
et
al
progress
made
structur
organ
wnv
provid
insight
molecular
transit
occur
viru
life
cycl
mukhopadhyay
et
al
threedimension
reconstruct
imag
cryoelectron
microscopi
demonstr
wnv
wellorgan
outer
protein
shell
lipid
membran
bilay
lessdefin
inner
nucleocapsid
core
mukhopadhyay
et
al
icosahedr
scaffold
consist
e
protein
arrang
repeat
herringbon
pattern
kuhn
et
al
zhang
et
al
structur
analysi
solubl
ectodomain
wnv
e
protein
reveal
three
domain
kanai
et
al
nybakken
et
al
consist
earlier
studi
relat
flavivirus
modi
et
al
rey
rey
et
al
domain
particip
conform
chang
associ
acidif
endosom
modi
et
al
domain
ii
contain
import
role
dimer
trimer
virusmedi
fusion
modi
et
al
modi
et
al
rey
et
al
domain
iii
adopt
immunoglobulinlik
fold
contain
distal
project
loop
matur
virion
mukhopadhyay
et
al
zhang
et
al
zhang
et
al
hypothes
contain
bind
site
cell
attach
beasley
barrett
bhardwaj
et
al
rey
et
al
roehrig
et
al
e
monom
lay
rel
flat
along
virion
surfac
set
three
antiparallel
homodim
matur
flaviviru
virion
quasiicosahedr
symmetri
three
e
monom
found
asymmetr
unit
result
distinct
chemic
environ
avail
antibodi
receptor
bind
strongli
neutral
typespecif
antibodi
wnv
gener
mice
recogn
epitop
domain
iii
e
protein
beasley
barrett
choi
et
al
li
et
al
oliph
et
al
sanchez
et
al
volk
et
al
crystal
structur
fab
fragment
neutral
antibodi
complex
domain
iii
wnv
e
protein
provid
structur
insight
typespecif
antibodi
neutral
fab
fragment
engag
four
discontinu
segment
domain
iii
includ
ntermin
region
residu
three
strandconnect
loop
bc
de
fg
comparison
avail
wnv
sequenc
reveal
nearli
complet
conserv
structur
defin
epitop
sequenc
analysi
flavivirus
reveal
divers
four
segment
epitop
individu
flavivirusspecif
neutral
antibodi
map
analog
bind
region
domain
iii
hiramatsu
et
al
sukupolvipetti
et
al
volk
et
al
wu
et
al
structur
epitop
although
specif
individu
flavivirus
may
import
role
neutral
flavivirus
recent
studi
human
chimpanze
deriv
monoclon
antibodi
wnv
relat
flavivirus
suggest
addit
strongli
neutral
antibodi
epitop
locat
within
di
didii
hing
along
diidim
interfac
goncalvez
et
al
lai
et
al
vogt
et
al
infect
experi
anim
contribut
understand
pathogenesi
wnv
enceph
review
base
studi
relat
flavivirus
initi
replic
mosquito
inocul
believ
occur
skin
dendrit
cell
ho
et
al
librati
et
al
marovich
et
al
wu
et
al
infect
cell
migrat
drain
lymph
node
johnston
et
al
infect
risk
dissemin
counter
develop
earli
immun
respons
purtha
et
al
reach
secondari
lymphoid
tissu
new
round
infect
occur
lead
entri
circul
via
effer
lymphat
system
thorac
duct
viremia
ensu
spread
viscer
organ
eg
kidney
spleen
wnv
cross
bloodbrain
barrier
enter
central
nervou
system
diamond
et
al
wang
et
al
xiao
et
al
incomplet
understood
mechan
although
wnv
like
enter
central
nervou
system
via
hematogen
rout
diamond
et
al
johnson
mim
perhap
result
matrix
induc
chang
capillari
permeabl
wang
et
al
mechan
entri
includ
retrograd
axon
transport
peripher
nerv
samuel
et
al
transport
across
brain
microvascular
endothelium
verma
et
al
activ
replic
endotheli
cell
verma
et
al
trojan
hors
mechan
wnv
carri
brain
infect
inflammatori
cell
burk
monath
dai
et
al
wang
et
al
anim
model
wnv
first
identifi
central
nervou
system
three
four
day
infect
infecti
west
nile
viru
detect
multipl
site
brain
spinal
cord
patchi
infect
neuron
observ
cerebr
cortex
hippocampu
basal
ganglia
cerebellum
brain
stem
anterior
horn
spinal
cord
diamond
et
al
xiao
et
al
neuron
infect
associ
degener
loss
cell
architectur
associ
apoptosi
samuel
et
al
correl
develop
microgli
nodul
surround
infect
neuron
later
cours
infect
mononuclear
cell
infiltr
appear
diffus
throughout
infect
region
although
clear
whether
inflammatori
cell
erad
infect
contribut
pathogenesi
destroy
infect
neuron
releas
potenti
toxic
cytokin
gett
et
al
note
purkinj
neuron
cerebellum
diamond
et
al
xiao
et
al
zhang
et
al
motor
neuron
spinal
cord
highli
vulner
morrey
et
al
samuel
et
al
siddharthan
et
al
inde
virul
north
american
strain
west
nile
viru
caus
poliolik
syndrom
human
predominantli
affect
lower
motor
neuron
function
glass
et
al
lei
et
al
lei
et
al
infect
neuron
caus
vacuol
prolifer
rough
endoplasm
reticulum
golgideriv
membran
apoptosi
express
wnv
protein
may
directli
induc
apoptot
cell
death
neuron
samuel
et
al
shrestha
et
al
possibl
due
activ
unfold
protein
respons
pathway
medigeshi
et
al
accumul
west
nile
viru
capsid
yang
et
al
yang
et
al
ramanathan
et
al
protein
caus
apoptosi
activ
caspas
although
immunocompromis
statu
predispos
sever
diseas
human
individu
risk
factor
beyond
aforement
gene
fulli
character
sever
wnv
infect
increas
immunosuppress
patient
bode
et
al
chantack
forrest
kumar
et
al
kumar
et
al
murray
et
al
suggest
essenti
role
immun
control
mechan
high
incid
wnv
neuroinvas
diseas
patient
antit
cell
therapi
kleinschmidtdemast
et
al
mice
cell
defici
brien
et
al
brien
et
al
purtha
et
al
shrestha
diamond
sitati
diamond
wang
et
al
indic
integr
adapt
cellular
immun
respons
essenti
clearanc
wnv
b
cell
also
protect
dissemin
infect
scid
mice
b
cell
defici
mice
uniformli
succumb
wnv
infect
chamber
et
al
diamond
et
al
diamond
et
al
halevi
et
al
humor
immun
link
peripher
clearanc
wnv
wherea
cell
appear
critic
clearanc
within
cn
exampl
cell
defici
mice
exhibit
increas
wnv
enceph
serum
viral
load
igm
level
differ
wildtyp
anim
cell
traffick
andor
function
cn
impair
sitati
diamond
indic
surviv
sole
function
prevent
cn
dissemin
also
clear
past
five
year
provid
new
perspect
differ
compon
innat
immun
respons
restrict
wnv
infect
host
cell
recogn
respond
rna
viru
infect
endosom
nucleic
acid
sensor
tolllik
receptor
cytoplasm
dsrna
sensor
retino
acidinduc
gene
rigi
melanomadifferentiationassoci
gene
colonna
kawai
akira
bind
rna
pathogen
recognit
receptor
prr
result
downstream
activ
transcript
factor
interferon
regulatori
factor
express
ifn
ifnstimul
gene
isg
prr
demonstr
specif
differ
rna
viru
famili
rigi
essenti
ifn
respons
respons
flaviviru
infect
kato
et
al
cultur
fibroblast
defici
rigi
demonstr
delay
induct
host
respons
decreas
activ
augment
wnv
replic
fredericksen
gale
fredericksen
et
al
fredericksen
et
al
vivo
howev
may
less
essenti
cellular
recognit
host
respons
ifn
product
myeloid
dendrit
cell
remain
larg
intact
wnv
infect
gitlin
et
al
system
product
mice
appear
larg
independ
transcript
factor
daffi
et
al
depend
daffi
et
al
individu
cell
type
myeloid
fibroblast
neuron
use
respons
protect
wnv
infect
ifndepend
independ
pathway
daffi
et
al
cell
gener
robust
ifn
respons
wnv
infect
absenc
altern
set
prr
transcript
regul
like
use
includ
recognit
wnv
tlr
mediat
like
bind
viral
dsrna
bind
ssrna
includ
uridinerich
rna
motif
activ
respons
viral
infect
induc
product
type
ifn
alexopoul
et
al
diebold
et
al
howev
signal
pathway
util
differ
recruit
adaptor
protein
form
complex
complex
recruit
kinas
activ
kinas
activ
andor
recruit
trif
stimul
induct
type
ifn
gene
via
interact
despit
sever
vitro
studi
show
bind
dsrna
vitro
regul
ifn
cytokin
respons
role
protect
viral
infect
vivo
remain
less
clear
conflict
result
observ
wnv
infect
mice
two
studi
use
mice
report
somewhat
oppos
phenotyp
wang
colleagu
show
detriment
role
defici
mice
improv
surviv
rate
wnv
infect
associ
mildli
increas
wnv
burden
peripher
tissu
yet
decreas
proinflammatori
cytokin
respons
diminish
inflammatori
respons
reduc
bloodbrain
barrier
permeabl
direct
entri
wnv
brain
contrast
studi
show
protect
role
decreas
surviv
mice
wnv
infect
mildli
elev
viral
titer
peripher
tissu
earli
viral
entri
cn
daffi
et
al
present
remain
unclear
result
discord
although
dispar
rout
inocul
passag
histori
viru
could
impact
cytokin
respons
appear
independ
role
cn
potenti
restrict
wnv
replic
neuron
cortic
neuron
sustain
enhanc
wnv
viral
replic
although
type
ifn
respons
normal
microglia
astrocyt
show
reduc
activ
product
proinflammatori
cytokin
poli
c
challeng
kim
et
al
town
et
al
thu
exact
contribut
wnv
protect
requir
studi
like
involv
direct
effect
cn
initi
identifi
trigger
respons
exposur
ssrna
influenza
virus
hornung
et
al
also
character
primari
prr
respons
system
ifn
product
plasmacytoid
dc
pathway
asselinpaturel
trinchieri
contribut
protect
wnv
infect
vivo
recent
examin
town
et
al
mice
vulner
wnv
infect
sustain
increas
viremia
infect
mice
show
defect
immun
cell
home
wnvinfect
tissu
via
novel
mechan
interestingli
system
level
proinflammatori
cytokin
type
ifn
higher
mice
compar
wild
type
anim
result
suggest
abrog
pathway
littl
system
impact
ifn
product
wnv
infect
complement
system
famili
serum
protein
cell
surfac
molecul
particip
pathogen
recognit
clearanc
complement
contribut
host
protect
direct
oposn
andor
cytolysi
chemotaxi
immun
clearanc
modul
b
cell
function
carrol
complement
requir
protect
lethal
wnv
infect
mice
wnv
activ
complement
vivo
mice
lack
central
complement
compon
complement
receptor
cr
show
enhanc
lethal
wnv
infect
mehlhop
diamond
mehlhop
et
al
three
complement
activ
pathway
coordin
control
wnv
mice
defici
molecul
altern
classic
lectin
pathway
exhibit
increas
mortal
interestingli
activ
pathway
modul
wnv
infect
distinct
mechan
altern
pathway
defici
mice
demonstr
normal
b
cell
function
impair
cell
respons
wherea
classic
lectin
pathway
defici
mice
defect
wnvspecif
antibodi
product
cell
respons
mehlhop
diamond
complement
also
augment
efficaci
igg
antibodi
wnv
wherea
initi
studi
antiwnv
igm
antibodi
suggest
complement
could
effici
enhanc
wnv
infect
macrophag
vitro
cardosa
et
al
cardosa
et
al
recent
investig
indic
complement
compon
augment
potenc
neutral
antibodi
wnv
igg
subclassspecif
manner
e
mehlhop
nelson
pierson
diamond
manuscript
submit
analog
observ
virus
includ
measl
iankov
et
al
influenza
feng
et
al
mozdzanowska
et
al
vesicular
stomat
beeb
cooper
human
immunodefici
aasachapman
et
al
spruth
et
al
virus
also
restrict
antibodydepend
enhanc
wnv
infect
vitro
vivo
mehlhop
et
al
studi
directli
address
function
cellular
innat
immun
wnv
infect
macrophag
dendrit
cell
like
inhibit
wnv
though
direct
viral
clearanc
enhanc
antigen
present
cytokin
chemokin
secret
consist
deplet
myeloid
cell
system
drain
lymph
node
enhanc
lethal
mice
wnv
infect
bennathan
et
al
purtha
et
al
macrophag
basal
express
key
host
defens
molecul
includ
rigi
thu
restrict
wnv
infect
induc
type
ifn
daffi
et
al
inhibitori
cytokin
macrophag
may
also
control
flavivirus
product
nitric
oxid
intermedi
kreil
eibl
lin
et
al
although
role
wnv
infect
establish
cell
also
function
earli
immun
respons
directli
limit
wnv
infect
lack
mhc
restrict
cell
react
viral
antigen
absenc
convent
antigen
process
steel
et
al
cell
expand
follow
wnv
infect
welt
et
al
increas
viral
burden
mortal
delay
prime
adapt
immun
respons
observ
mice
defici
cell
wang
et
al
bone
marrow
chimera
reconstitut
experi
demonstr
cell
requir
limit
wnv
infect
shrestha
et
al
natur
killer
nk
cell
also
potenti
control
wnv
infect
recognit
elimin
virusinfect
cell
nk
cell
activ
transient
activ
suppress
follow
flaviviru
infect
mice
shresta
et
al
vargin
semenov
wnv
infect
increas
surfac
express
class
mhc
molecul
enhanc
transport
activ
tap
transcript
activ
mhc
class
gene
dougla
et
al
king
kesson
liu
et
al
natur
kill
may
inhibit
diamond
king
kesson
king
et
al
notabl
antibodi
deplet
nk
cell
mice
alter
morbid
mortal
wnv
infect
chung
et
al
shrestha
et
al
present
specif
therapi
approv
use
human
wnv
infect
current
treatment
support
tissu
cultur
anim
model
studi
appli
multipl
strategi
gener
novel
therapi
wnv
possibl
flavivirus
nonetheless
develop
therapeut
mitig
abort
diseas
challeng
patient
sever
diseas
often
underli
immun
deficit
present
clinic
attent
rel
late
cours
granwehr
et
al
jackson
among
addit
impedi
develop
therapeut
effici
cross
central
nervou
system
clear
viru
infect
neuron
final
candid
agent
identifi
regulatori
hurdl
encount
design
implement
multicent
trial
given
sporad
tempor
spatial
occurr
wnv
infect
jester
et
al
ribavirin
broadspectrum
antivir
agent
use
clinic
treat
respiratori
syncyti
hall
et
al
hepat
c
davi
et
al
lassa
mccormick
et
al
hantaan
huggin
et
al
la
cross
mcjunkin
et
al
virus
act
guanosin
analogu
competit
inhibit
inosin
monophosph
dehydrogenas
imp
result
deplet
intracellular
guanosin
pool
leyssen
et
al
may
interfer
guanylyl
step
rna
cap
inhibit
viral
polymeras
compromis
integr
viral
genom
incorpor
directli
nascent
rna
strand
serv
templat
cytidin
uridin
crotti
et
al
day
et
al
ribavirin
inhibitori
activ
wnv
infect
cell
cultur
anderson
rahal
day
et
al
jordan
et
al
high
dose
ec
limit
anim
studi
perform
less
promis
result
treatment
wnvinfect
hamster
ribavirin
increas
mortal
morrey
et
al
moreov
wnv
outbreak
israel
patient
receiv
ribavirin
high
mortal
rate
observ
group
chower
et
al
mycophenol
acid
mpa
nonnucleosid
inhibitor
imp
dehydrogenas
use
clinic
prevent
reject
transplant
organ
immunosuppress
properti
mpa
attribut
antiprolif
effect
lymphocyt
vitro
allison
eugui
nagi
et
al
mpa
inhibit
vari
degre
replic
number
dna
rna
retrovirus
vitro
includ
arenavirus
sindbi
viru
reoviru
parainfluenza
viru
coxsacki
viru
epsteinbarr
viru
hepat
b
viru
hiv
gong
et
al
ichimura
levi
neyt
de
clercq
four
studi
demonstr
mpa
inhibit
flaviviru
infect
includ
wnv
cell
limit
viral
rna
replic
diamond
et
al
morrey
et
al
ng
et
al
takhampunya
et
al
although
mpa
block
wnv
infect
effici
cell
cultur
vivo
inhibitori
properti
overshadow
immunosuppress
effect
increas
mortal
wnv
infect
observ
mice
treat
sever
differ
dose
mpa
b
geiss
diamond
unpublish
result
thu
preclin
data
suggest
inhibitor
guanosin
biosynthesi
therapeut
candid
wnv
infect
like
effect
immun
system
function
type
ifn
compris
import
innat
immun
system
control
viral
infect
ifn
induc
antivir
state
within
cell
induct
antivir
protein
modul
adapt
immun
respons
samuel
pretreat
cell
vitro
type
ifn
potent
inhibit
flavivirus
includ
wnv
anderson
rahal
best
et
al
cranc
et
al
diamond
harri
diamond
et
al
fredericksen
et
al
howev
inhibitori
effect
ifn
markedli
attenu
viral
replic
begun
diamond
et
al
lin
et
al
flaviviru
nonstructur
protein
antagon
type
ifn
effect
prevent
phosphoryl
signal
gene
transcript
ashour
et
al
best
et
al
evan
seeger
jone
et
al
lin
et
al
lin
et
al
liu
et
al
liu
et
al
liu
et
al
munozjordan
et
al
munozjordan
et
al
nonetheless
ifn
may
still
therapeut
potenti
mice
defici
receptor
acut
vulner
wnv
infect
mortal
mean
time
death
day
subcutan
inocul
pfu
viru
pretreat
rodent
inhibit
st
loui
enceph
viru
infect
result
decreas
wnv
viral
load
mortal
brook
phillpott
morrey
et
al
treatment
reduc
complic
human
st
loui
enceph
viru
case
use
uncontrol
manner
treat
small
number
human
case
wnv
enceph
kalil
et
al
lewi
amsden
rahal
et
al
sayao
et
al
nonetheless
vietnam
doubleblind
random
placebo
control
clinic
trial
perform
children
suspect
document
japanes
enceph
viru
infect
treatment
ifn
fail
improv
outcom
solomon
et
al
although
antibodi
util
therapeut
sever
viral
infect
sawyer
zeitlin
et
al
except
prophylact
use
tickborn
enceph
viru
use
extens
flaviviru
infect
human
neutral
antibodi
recogn
structur
e
protein
although
subset
also
describ
anoth
virionassoci
protein
prm
membran
protein
colombag
et
al
falconar
pincu
et
al
vazquez
et
al
sever
group
also
gener
nonneutr
yet
protect
mab
chung
et
al
chung
et
al
despr
et
al
falgout
et
al
henchal
et
al
putnak
schlesing
schlesing
et
al
schlesing
et
al
schlesing
et
al
schlesing
chapman
protein
absent
virion
thu
protect
flaviviru
infect
vivo
alway
correl
neutral
activ
vitro
roehrig
et
al
schlesing
et
al
abil
cure
rodent
flaviviru
infect
immun
serum
monoclon
antibodi
depend
dosag
time
administr
camenga
et
al
chiba
et
al
kimurakuroda
yasui
oliph
et
al
phillpott
et
al
roehrig
et
al
polyclon
antibodi
prevent
infect
one
flaviviru
provid
durabl
crossprotect
heterolog
flavivirus
broom
et
al
roehrig
et
al
although
studi
suggest
antibodi
could
potenti
therapeut
role
least
theoret
concern
treatment
could
exacerb
diseas
subneutr
concentr
antibodi
enhanc
flaviviru
replic
myeloid
cell
vitro
cardosa
et
al
cardosa
et
al
gollin
porterfield
gollin
porterfield
peiri
porterfield
peiri
et
al
peiri
et
al
pierson
et
al
vivo
mehlhop
et
al
thu
could
complic
antibodi
therapi
phenomenon
antibodydepend
enhanc
infect
ade
may
caus
patholog
cytokin
cascad
occur
secondari
dengu
viru
infect
halstead
halstead
et
al
kuran
enni
moren
despit
extens
character
vitro
signific
ade
vivo
wnv
flavivirus
remain
uncertain
apart
perhap
relat
ade
earlydeath
phenomenon
moren
report
could
also
limit
util
antibodi
therapi
accord
model
anim
preexist
humor
immun
respond
well
viral
challeng
may
succumb
infect
rapidli
anim
without
preexist
immun
although
describ
passiv
acquisit
antibodi
yellow
fever
langat
enceph
virus
barrett
gould
gould
et
al
gould
buckley
webb
et
al
phenomenon
observ
transfer
monoclon
polyclon
antibodi
japanes
kimurakuroda
yasui
tickborn
kreil
eibl
passiv
administr
antiwnv
antibodi
protect
therapeut
caus
advers
effect
relat
immun
enhanc
transfer
immun
serum
prior
wnv
infect
protect
wild
type
b
celldefici
bcell
defici
mice
infect
diamond
et
al
increas
mortal
observ
even
subneutr
concentr
antibodi
use
similarli
passiv
administr
immun
serum
tesh
et
al
antiserum
recogn
wnv
e
protein
protect
hamster
mice
lethal
wnv
infect
therapeut
trial
immun
human
protect
mice
wnvinduc
mortal
bennathan
et
al
bennathan
et
al
engl
diamond
juland
et
al
therapeut
intervent
even
five
day
infect
reduc
mortal
time
point
signific
wnv
spread
brain
spinal
day
thu
passiv
transfer
immun
antibodi
improv
clinic
outcom
even
wnv
dissemin
cn
small
number
human
patient
receiv
immunotherapi
wnv
infect
prophylaxi
therapi
neutral
antiwnv
antibodi
may
possibl
intervent
elderli
immunocompromis
case
report
haley
et
al
hamdan
et
al
saquib
et
al
shimoni
et
al
document
improv
human
neuroinvas
wnv
infect
receiv
immun
isra
donor
given
endem
natur
wnv
middl
east
pool
human
immunoglobulin
isra
donor
shown
contain
signific
neutral
titer
antibodi
wnv
bennathan
et
al
bennathan
et
al
engl
diamond
although
promis
immunotherapi
wnv
infect
human
limit
batch
variabl
may
affect
quantit
titer
function
activ
therapeut
efficaci
specif
antibodi
prepar
b
purifi
human
blood
plasma
inher
risk
transmit
known
unknown
infecti
agent
c
requir
larg
volum
administr
increas
advers
event
patient
cardiac
renal
comorbid
overcom
limit
human
human
monoclon
antibodi
antibodi
fragment
therapeut
activ
wnv
infect
oliph
et
al
throsbi
et
al
vogt
et
al
develop
sever
group
human
human
antibodi
fragment
high
neutral
activ
vitro
provid
excel
protect
vivo
mice
mab
effect
therapi
wnv
enceph
function
onset
symptom
ideal
infect
central
nervou
system
mous
human
mab
given
singl
dose
five
six
day
infect
mice
hamster
protect
morrey
et
al
morrey
et
al
oliph
et
al
acut
flaccid
paralysi
hamster
also
block
treatment
one
neutral
mab
sever
day
infect
samuel
et
al
macrogen
initi
phase
iii
random
doubleblind
clinic
trial
evalu
safeti
efficaci
antibodi
also
term
sever
wnv
infect
http
thu
neutral
antibodi
therapeut
show
promis
directli
inhibit
transneuron
spread
wnv
infect
prevent
develop
paralysi
vivo
futur
use
combin
monoclon
antibodi
bind
distinct
epitop
neutral
independ
mechan
could
diminish
potenti
risk
select
escap
variant
vivo
zhang
et
al
especi
immunocompromis
individu
gener
highgrad
viremia
tissu
viral
burden
rna
interferencerna
interfer
rnai
cellular
process
specif
degrad
rna
within
cytoplasm
cell
sequencespecif
manner
meister
et
al
rnai
occur
plant
nematod
parasit
insect
mammalian
cell
believ
function
regul
cellular
gene
express
possibl
innat
defens
rna
virus
voinnet
waterhous
et
al
rnai
use
doubl
strand
rna
dsrna
target
degrad
sequencespecif
singlestrand
rna
cytoplasm
ribonucleas
dicer
recogn
cleav
long
dsrna
molecul
base
pair
small
interf
rna
sirna
molecul
associ
rna
induc
silenc
complex
risc
target
degrad
complementari
singlestrand
rna
molecul
sontheim
rnai
wide
use
transient
disrupt
variou
gene
product
studi
function
cell
mani
mammalian
virus
appear
suscept
treatment
exogen
sirna
cell
express
virusspecif
sirna
resist
infect
wnv
anthoni
et
al
bai
et
al
geiss
et
al
mccown
et
al
ong
et
al
yang
et
al
vitro
sequenc
specif
activ
sirna
virus
led
great
interest
potenti
new
class
antivir
therapi
two
studi
shown
administr
sirna
mice
reduc
wnv
load
afford
partial
protect
lethal
challeng
bai
et
al
kumar
et
al
studi
also
perform
determin
whether
wnvspecif
sirna
could
act
effici
therapeut
administ
viral
challeng
although
sirna
could
protect
lethal
infect
given
within
hour
infect
kumar
et
al
signific
differ
surviv
observ
sirna
deliv
hour
infect
bai
et
al
vitro
studi
may
explain
attenu
therapeut
effect
sirna
pretreat
posttreat
cell
sirna
greatli
reduc
wnv
replic
infect
flavivirus
replic
special
membran
compart
welsch
et
al
genom
may
expos
cytoplasm
rnai
machineri
rnai
base
therapeut
wnv
may
await
develop
enhanc
deliveri
system
allow
sirna
effici
cross
intracellular
membran
inhibit
activ
replic
virus
antisens
technologyantisens
oligom
use
modul
gene
express
pathogen
virus
sever
clinic
develop
trial
kinney
et
al
et
al
class
compound
inhibit
virus
bind
rna
sequenc
specif
manner
effect
block
access
particular
region
viral
genom
develop
phosphorodiamid
morpholino
oligom
pmo
overcom
prior
limit
enhanc
water
solubl
nucleas
resist
summerton
et
al
conjug
argininerich
peptid
pmo
facilit
cellular
uptak
inhibitori
activ
cell
cultur
system
neuman
et
al
sequencespecif
antisens
oligom
inhibitori
activ
sever
flavivirus
includ
wnv
cell
cultur
dea
et
al
kinney
et
al
raviprakash
et
al
stein
shi
low
micromolar
concentr
arginin
rich
peptideconjug
pmo
target
untransl
cycliz
sequenc
inhibit
wnv
log
pfuml
dea
et
al
kinney
et
al
howev
effect
suppress
viral
replic
vitro
requir
pmo
present
soon
infect
administr
either
day
infect
littl
antivir
effect
pmo
direct
conserv
sequenc
partial
protect
mice
wnv
diseas
without
caus
appreci
toxic
although
select
resist
mutant
observ
dea
et
al
clinic
improv
observ
even
ppo
administ
mice
day
infect
although
statist
signific
differ
achiev
avi
biopharma
initi
phase
iii
human
clinic
studi
treatment
wnv
infect
http
trial
random
doubleblind
studi
focus
determin
safeti
toler
pharmacokinet
potenti
efficaci
hemagglutinin
influenza
viru
prototyp
class
viral
envelop
fusion
protein
respons
receptor
engag
acid
ph
helic
viral
hemagglutinin
rearrang
expos
ntermin
fusion
peptid
facilit
fusion
two
lipid
membran
viral
entri
carr
kim
importantli
peptid
mimic
class
fusion
protein
hiv
sodroski
sendai
rapaport
et
al
newcastl
young
et
al
herp
okazaki
kida
virus
effici
inhibit
entri
infect
inde
fusion
inhibitor
approv
clinic
use
hivinfect
patient
flaviviru
e
protein
structur
distinct
class
fusion
protein
togeth
envelop
protein
alphavirus
compris
second
class
viral
fusion
protein
class
ii
fusion
protein
facilit
viral
entri
nucleocapsid
releas
undergo
analog
seri
phdepend
conform
chang
bressanelli
et
al
kuhn
et
al
lescar
et
al
modi
et
al
use
algorithm
predict
peptid
inhibitor
class
fusion
protein
one
group
identifi
inhibitori
peptid
wnv
dengu
viru
e
protein
correspond
propos
fusion
stem
anchor
domain
low
micromolar
concentr
peptid
inhibit
wnv
dengu
viru
infect
cell
cultur
sequencespecif
manner
hrobowski
et
al
altern
approach
anoth
group
identifi
two
e
protein
peptid
could
inhibit
wnv
infect
valu
low
mice
challeng
wnv
administ
inhibitori
peptid
show
reduc
viremia
lethal
bai
et
al
flaviviru
assembl
take
place
within
endoplasm
reticulum
er
structur
glycoprotein
prm
e
local
lumin
side
er
encapsid
immatur
particl
prm
e
heterodimer
complex
chamber
et
al
zhang
et
al
flavivirusinfect
mammalian
cell
oligosaccharid
glc
man
glcnac
ad
er
specif
asparagin
residu
specif
prm
e
protein
high
mannos
carbohydr
sequenti
modifi
er
golgi
resid
glucosidas
gener
nlink
glycan
lack
termin
glucos
residu
hebel
et
al
trim
nlink
carbohydr
er
requir
proper
assembl
secret
flavivirus
courageot
et
al
wu
et
al
imino
sugar
deriv
deoxynorjirimycin
castanospermin
inhibit
endoplasm
reticulum
ii
prevent
process
high
mannos
nlink
glycan
nascent
glycoprotein
step
requir
interact
er
chaperon
calnexin
calreticulin
sever
flavivirus
strongli
inhibit
inhibitor
vitro
vivo
courageot
et
al
schul
et
al
whitbi
et
al
wu
et
al
recent
famili
imino
sugar
deriv
synthes
superior
antivir
activ
mm
low
toxic
select
index
sever
flavivirus
includ
wnv
one
possibl
advantag
inhibitor
target
host
enzym
essenti
step
viru
secret
rather
viru
directli
thu
less
like
select
resist
variant
last
five
year
highthroughput
screen
small
molecul
librari
perform
sever
group
identifi
class
druggabl
compound
inhibit
wnv
inhibitor
identifi
attenu
wnv
translat
proteas
activ
replic
borowski
et
al
goodel
et
al
gu
et
al
johnston
et
al
nouieri
et
al
puigbasago
et
al
gu
et
al
gu
et
al
use
cellbas
wnv
subgenom
replicon
screen
compound
identifi
pyrozolopyrimidin
compound
antiwnv
activ
puigbasago
et
al
use
full
length
wnv
express
luciferas
report
gene
identifi
triaryl
pyrazolin
compound
inhibit
flaviviru
rna
replic
ec
noueiri
et
al
nouieri
et
al
evalu
chemic
librari
compound
abil
inhibit
report
gene
express
wnv
replicon
identifi
inhibitori
secondari
sulfonamid
cyclopenta
pyridin
valu
johnston
et
al
johnston
et
al
screen
compound
librari
abil
inhibit
proteas
identifi
common
scaffold
noncompetit
inhibitor
wnv
proteas
activ
analog
mueller
et
al
mueller
et
al
util
highthroughput
assay
screen
compound
inhibit
wnv
proteas
lead
compound
famili
bound
substrat
cleft
inhibit
proteas
fewer
studi
perform
small
molecul
anim
assess
therapeut
potenti
one
oral
pyrazin
deriv
broadspectrum
antivir
activ
protect
rodent
administ
twice
daili
begin
two
day
wnv
infect
morrey
et
al
howev
administr
day
infect
show
littl
appar
efficaci
anoth
preliminari
studi
show
oral
activ
hexos
could
protect
lethal
wnv
infect
young
old
mice
augment
earli
antibodi
cell
respons
although
postexposur
therapeut
trial
perform
rais
possibl
dietari
supplement
oral
activ
form
hexos
could
improv
antivir
immun
respons
decreas
risk
sever
neuroinvas
wnv
diseas
given
lack
exist
therapi
continu
global
emerg
develop
antivir
agent
wnv
essenti
present
sever
candid
therapi
act
distinct
mechan
move
variou
stage
preclin
develop
base
epidemiolog
pathogenesi
sever
wnv
infect
effect
antivir
agent
wnv
must
minim
detriment
effect
immun
system
function
even
identif
new
class
antiwnv
agent
major
hurdl
remain
whether
administ
time
manner
extens
irrevers
neuron
injuri
occur
technic
challeng
includ
creat
inhibitor
effici
cross
bloodbrainbarri
allow
control
wnv
replic
within
neuron
regulatori
hurdl
encount
implement
multicent
trial
may
difficult
defin
referr
site
recruit
adequ
number
patient
statist
meaning
data
acquir
analyz
unlik
diseas
high
incid
may
take
year
complet
wnv
clinic
trial
introduct
sever
class
candid
antivir
agent
may
competit
patient
cohort
extens
preclin
experi
small
anim
hors
nonhuman
primat
may
use
defin
whether
candid
therapeut
wnv
reach
human
clinic
trial
ongo
pathogenesi
infect
studi
undoubtedli
inform
novel
drug
design
strategi
target
individu
viral
protein
dong
et
al
experi
anim
continu
defin
essenti
compon
protect
immun
respons
immunolog
risk
factor
predispos
sever
neurolog
diseas
ultim
combin
drug
strategi
block
viral
replic
boost
protect
immun
respons
minim
neuron
injuri
limit
develop
resist
variant
like
effect
singl
agent
